Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

(2014) Sven de Vos et al.   Journal of Hematology & Oncology

Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma

(2011) T. S. Lewis et al.   CLINICAL CANCER RESEARCH

CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma

(2011) B. Burington et al.   Science Translational Medicine

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

(2011) J. W. Friedberg   Hematology-American Society of Hematology Education Program

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

(2008) Arturo Molina   Annual Review of Medicine

Use of rituximab in diffuse large B-cell lymphoma in the salvage setting

(2008) Christian Gisselbrecht   BRITISH JOURNAL OF HAEMATOLOGY